Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer’s disease. The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer’s disease. Newt’s guest is Dr. Marwan Sabbagh, MD. He is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.
See omnystudio.com/listener for privacy information.
Episode 544: The Meaning of Easter
Episode 543: Donald Trump and the Tyranny of the Left
Episode 542: Modernizing the Pentagon
Episode 541: Shannon Bream on Love Stories of the Bible
Episode 540: Steve Krakauer on Uncovered
Episode 539: Putin and Xi
Episode 538: Parents of the World, Unite!
Episode 537: Trump vs. Soros DA Alvin Bragg
Episode 536: Mexican Drug Cartels – Part 2
Episode 535: Mexican Drug Cartels – Part 1
Episode 534: The State of the Economy: SVB, Interest Rates, and Protecting Your Retirement
Episode 533: Newt Answers Your Questions with Vivek Ramaswamy
Episode 532: Mike Pompeo on “Never Give An Inch”
Episode 531: James Rosen on Justice Scalia
Episode 530: The Federalist Papers
Episode 529: Lab Leak Most Likely Origin of COVID-19 Pandemic
Episode 528: Newt Answers Your Questions
Episode 527: Governor DeWine on Ohio’s Train Accident
Episode 526: War in Ukraine – One Year Later
Episode 525: Baltimore City Schools’ Failure to Educate
Create your
podcast in
minutes
It is Free